# PhecdaMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/phecdamed

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.phecdamed.com
- Latest round: Series A (Sep 26, 2025)
- Investors on record: 7

## About

Based in Hangzhou, China, and founded in 2021, PhecdaMed operates as a biopharmaceutical developer, specializing in mitochondrial research. The chief scientist as well as the chairman of the board, Hongguang Xia, is the vice chairman of the Biomedical Branch of the SCOC. The co-founder, Dong Liu, was the Associate Director of Hangzhou Tigermed Consulting Company Limited. In March 2023, the company was recognized as a National Science and Technology-based Small and Medium-sized Enterprise (SME). Its drugs have been clinically licensed by the National Drug Administration (NMPA) and the U.S. Food and Drug Administration (FDA). In September 2025, PhecdaMed raised Series A+ funding from new investors Zhejiang Yuhang Industrial Transformation & Upgrading Investment and Sunz Fund, returning investor Lapam Capital also participated in this round.
The company focuses on the small molecule selective mitochondrial autophagy inducers and tumor immune enhancers. It launched mitochondrial autophagy inducer small molecule compound TJ0113. The drug can be used in curing kidney disease, autoimmune disease, and aging-related diseases.
Revenue is generated from licensing of drug candidates, government grants, and strategic partnerships with pharmaceutical companies. Additional income may come from clinical trial collaborations and milestone-based funding.

## Funding rounds

- Series A, Sep 26, 2025 — Sunz Fund, Lapam Capital, Zhejiang Yuhang Industrial Transformation & Upgrading Investment
- Series A, Jun 23, 2023 — Xinghua Dingli Capital, Zhejiang Taimin Investment
- Angel, Sep 1, 2021 — Dynamic Capital, Million Capital

## Investors

- Dynamic Capital (https://capitalatlas.ai/funds/dynamic-capital) — Angel
- Million Capital — Angel
- Xinghua Dingli Capital (https://capitalatlas.ai/funds/xinghua-dingli-capital) — Series A
- Zhejiang Taimin Investment — Series A
- Sunz Fund (https://capitalatlas.ai/funds/sunz-fund) — Series A
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A
- Zhejiang Yuhang Industrial Transformation & Upgrading Investment — Series A